Company intelligence / Profile preview

Jiangsu Nutai Biologics Co., Ltd.

Not explicitly stated; likely Taizhou or Nanjing based on regional biotech activity but not confirmed, Jiangsu, Chinalink.springer.com ↗

Ownership: Private
Development stage: Other

Overview

Jiangsu Nutai Biologics Co., Ltd. has initiated a Phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of its SXRN Plasmid DNA Technique in patients with advanced solid tumors. The trial began recruiting in December 2024 and remains active as of April 2025. No published clinical results are available yet.[2][3][8]

Therapeutic areas: Oncology
Modalities: Plasmid DNAbiologic therapies[8][3]
Industry: Biotech

Drug pipeline

3 assets

SXRN

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025

Beyond the preview

Go deeper on Jiangsu Nutai Biologics Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Nutai Biologics Co., Ltd..

Explore the full profile